Healthcare Services

Chronic Rhinosinusitis With Nasal Polyps Market Revenue Expected to Reach $6.49 Billion by 2030 with 8% CAGR

March 31, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Chronic Rhinosinusitis With Nasal Polyps Market In 2026 And What Value Is Projected For 2030?

The chronic rhinosinusitis with nasal polyps market has shown robust expansion in recent years. It is anticipated to increase from $4.38 billion in 2025 to $4.78 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.0%. The historical growth in this sector is due to the escalating prevalence of chronic sinus disorders, expanded utilization of corticosteroid nasal sprays, a rise in consultations with ENT specialists, improved accessibility to diagnostic imaging, and greater awareness of inflammatory sinus diseases.

The chronic rhinosinusitis with nasal polyps market size is anticipated to experience substantial growth in the upcoming years. It is projected to reach $6.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.0%. This expansion during the forecast period can be attributed to factors such as increasing approvals of monoclonal antibody therapies, rising investment in ENT biologics research, the broadening scope of outpatient sinus surgery procedures, a growing emphasis on recurrence prevention, and increasing patient preference for non-surgical options. Significant trends foreseen in the forecast period include the increasing adoption of biologic therapies for CRSwNP, a rising utilization of minimally invasive surgical techniques, an intensified focus on long-term inflammation control, the expansion of personalized treatment pathways, and enhanced integration of diagnostic imaging and biomarkers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17113&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Chronic Rhinosinusitis With Nasal Polyps Market?

The escalating occurrence of respiratory diseases is projected to stimulate the expansion of the chronic rhinosinusitis with the nasal polyps market moving forward. These conditions encompass a wide array of ailments impacting the respiratory system, including the lungs and airways. A complex interaction of elements, such as air pollution, smoking, climate change, infections, occupational exposures, and allergies, contributes to the rising cases of respiratory illnesses. As more individuals experience conditions like asthma and chronic obstructive pulmonary disease (COPD), the incidence of associated conditions such as CRSwNP also climbs, leading to an elevated demand for diagnostic tools, treatments, and surgical interventions. For example, in December 2023, the National Center for Biotechnology Information, a US-based government agency, estimated that global COPD prevalence will reach nearly 600 million cases worldwide by 2050. Hence, the increasing prevalence of respiratory tract infections is anticipated to propel the growth of the chronic rhinosinusitis with nasal polyps market.

What Are The Key Segments Of The Chronic Rhinosinusitis With Nasal Polyps Market?

The chronic rhinosinusitis with nasal polyps market covered in this report is segmented –

1) By Treatment: Medications, Surgical Methods

2) By Route Of Administration: Nasal, Oral, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Medications: Corticosteroids (Nasal Sprays, Oral Steroids), Biologics (Monoclonal Antibodies Like Dupilumab)

2) By Surgical Methods: Endoscopic Sinus Surgery (ESS), Polypectomy (Polyps Removal), Balloon Sinuplasty

What Trends Are Affecting The Expansion Of The Chronic Rhinosinusitis With Nasal Polyps Market?

Leading companies in the chronic rhinosinusitis with nasal polyps market are increasingly focusing on alternative therapies, such as anti-IL-5 biologics, to improve patient outcomes and gain a competitive advantage. These anti-IL-5 biologics offer targeted therapy that reduces eosinophilic inflammation in diseases like severe asthma and eosinophilic disorders, improving symptom control and quality of life for patients. For instance, in March 2024, Optinose, a US-based pharmaceutical company specializing in developing and commercializing innovative products, received U.S. Food and Drug Administration (FDA) approval for its XHANCE. This prescription nasal spray is indicated for the treatment of chronic rhinosinusitis (CRS) in adults, specifically for both chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP). XHANCE contains fluticasone propionate, a corticosteroid that reduces inflammation in the nasal passages. A key feature is its unique Exhalation Delivery System (EDS), which allows patients to blow into the device while administering the spray, enhancing medication delivery deep into the nasal passages and effectively targeting areas where nasal polyps form and sinuses drain.

Who Are The Leading Companies Operating In The Chronic Rhinosinusitis With Nasal Polyps Market?

Major companies operating in the chronic rhinosinusitis with nasal polyps market are Pfizer Inc., Roche Holding AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Boehringer Ingelheim International GmbH, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Daiichi Sankyo Company Limited, Olympus Corporation, Eisai Co Ltd, Smith & Nephew PLC, Genentech USA Inc, Mallinckrodt Pharmaceuticals, Lyra Therapeutics Inc, Sunovion Pharmaceuticals, Acclarent Inc., Optinose US Inc, SinuSys Corporation, Biohaven Pharmaceuticals

Read the full chronic rhinosinusitis with nasal polyps market report here:

https://www.thebusinessresearchcompany.com/report/chronic-rhinosinusitis-with-nasal-polyps-global-market-report

What Are The Leading Geographic Regions In The Chronic Rhinosinusitis With Nasal Polyps Market?

North America was the largest region in the chronic rhinosinusitis with nasal polyps market in 2025. The regions covered in the chronic rhinosinusitis with nasal polyps market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Rhinosinusitis With Nasal Polyps Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17113&type=smp

Browse Through More Reports Similar to the Global Chronic Rhinosinusitis With Nasal Polyps Market 2026, By The Business Research Company

Pulmonary Arterial Hypertension Global Market Report

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Anti Hypertensive Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795